Abstract:Although Nature's antisense approaches are clearly impressive, this Perspectives article focuses on the experimental uses of antisense reagents (ASRs) for control of biological processes. ASRs comprise antisense oligonucleotides (ASOs), and their catalytically active counterparts ribozymes and DNAzymes, as well as small interfering RNAs (siRNAs). ASOs and ribozymes/DNAzymes target RNA molecules on the basis of Watson-Crick base pairing in sequence-specific manner. ASOs generally result in destruction of the target RNA by RNase-H mediated mechanisms, although they may also sterically block translation, also resulting in loss of protein production. Ribozymes and DNAzymes cleave target RNAs after base pairing via their antisense flanking arms. siRNAs, which contain both sense and antisense regions from a target RNA, can mediate target RNA destruction via RNAi and the RISC, although they can also function at the transcriptional level. A considerable number of ASRs (mostly ASOs) have progressed into clinical trials, although most have relatively long histories in Phase I/II settings. Clinical trial results are surprisingly difficult to find, although few ASRs appear to have yet established efficacy in Phase III levels. Evolution of ASRs has included: (a) Modifications to ASOs to render them nuclease resistant, with analogous modifications to siRNAs being developed; and (b) Development of strategies to select optimal sites for targeting. Perhaps the biggest barrier to effective therapies with ASRs is the "Delivery Problem." Various liposomal vehicles have been used for systemic delivery with some success, and recent modifications appear to enhance systemic delivery, at least to liver. Various nanoparticle formulations are now being developed which may also enhance delivery. Going forward, topical applications of ASRs would seem to have the best chances for success. In summary, modifications to ASRs to enhance stability, improve targeting, and incremental improvements in delivery vehicles continue to make ASRs attractive as molecular therapeutics, but their advance toward the bedside has been agonizingly slow.

The design of antisense peptides and its application in the treatment of diseases

Studies on drug targeting to nucleic acids

Antisense Technology - the Second Tidal of Biotechnology

ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION

[Current Status of Antisense Drugs].

Antisense Oligonucleotides: The State of the Art

Biomolecular Interactions Between Sense Peptides and Its Antisense Peptides of the Human Anaphyiatoxin C5a

Study on the Degeneracy of Antisense Peptides Using Affinity Chromatography.

Peptide Nucleic Acid──a New Anti-Sense Drug

Antisense Oligonucleotides: the glint of new antimicrobial agent

Design and Synthetic Strategies for Helical Peptides.

Antisense applications for biological control

Γ-Aapeptides As a New Class of Peptidomimetics: Design, Synthesis, and Applications

From Antisense to Antigene:an New Breach of Antigene Strategy

Peptide Antisense Nanoparticles

The application of antisense oligonucleotides in disease treatment

De Novo Design of Self-Assembled Hexapeptides As Β-Amyloid (aβ) Peptide Inhibitors.

Rational Design of Hybrid Peptides: A Novel Drug Design Approach

Synthetic peptides: promising modalities for the targeting of disease related nucleic acids

Progresses of Relationship Between Antimicrobial Peptide Structure and Function As Well As Its Molecular Design

Antisense and Functional Nucleic Acids in Rational Drug Development